MEC Plus Full List View

MEC Plus

Chronic Lymphocytic Leukemias
Chronic Lymphocytic Leukemias
Jose Sandoval Sus, MD, FACP
Chronic Lymphocytic Leukemias
Chronic Lymphocytic Leukemias
Jose Sandoval Sus, MD, FACP
B-Cell Lymphomas: Updates and Future Directions
B-Cell Lymphomas: Updates and Future Directions
Eduardo Sotomayor, MD
Multiple Myeloma
Multiple Myeloma
Sergio Giralt, MD
Multiple Myeloma
Multiple Myeloma
Sergio Giralt, MD
Metastatic Colorectal Cancer Therapy
Metastatic Colorectal Cancer Therapy
Richard D. Kim, MD
Gastric and Esophageal Cancer Updates
Gastric and Esophageal Cancer Updates
Caio Rocha-Lima, MD, MS
Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1 and Others in Liquid and Solid Tumor Specimens
Predictive and Prognostic Biomarkers for IO: Value of TMB, MSI, PD-L1 and Others in Liquid and Solid Tumor Specimens
Alberto Chiappori, MD
Clinical Utility and Future indications of Liquid Biopsies in Lung Cancer
Clinical Utility and Future indications of Liquid Biopsies in Lung Cancer
Benjamin Levy, MD
Stage III NSCLC: Beyond the PACIFIC/Novel Approaches
Stage III NSCLC: Beyond the PACIFIC/Novel Approaches
Jorge E. Gomez, MD
How to Choose Front Line Therapy for Metastatic Non-Driver Mutation NSCLC
How to Choose Front Line Therapy for Metastatic Non-Driver Mutation NSCLC
George R. Simon, MD, FACP, FCCP
Lung Cancer Neoadjuvant and Adjuvant Immunotherapy
Lung Cancer Neoadjuvant and Adjuvant Immunotherapy
Luis E Raez, MD, FACP, FCCP
Uncommon Mutations/Fusions: EGFRex20ins, RET, MET, Her2, NRG1
Uncommon Mutations/Fusions: EGFRex20ins, RET, MET, Her2, NRG1
Stephen V. Liu, MD